BlackRock, Inc. has increased its total holding in ChemoMetec A/S to 15.00%, crossing the 15 per cent threshold under Section 38 of the Danish Capital Markets Act. The Danish cell-counting instrument maker announced the change in a major shareholder disclosure dated 16 September 2026, stating that BlackRock reached the level on 14 September 2026. The announcement was made pursuant to Section 30 of the Capital Markets Act. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops, manufactures and markets instruments for cell counting and other measurements for the pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec A/SBlackRock raised its holding in ChemoMetec to 15%, crossing the major-shareholder threshold.
BlackRock IncBlackRock increased its stake in ChemoMetec to 15%, a portfolio/investment move rather than a company-specific development.
